| API | Active pharmaceutical ingredient |
| AUC | Area under the plasma (blood) curves |
| BCS | Biopharmaceutics Classification System |
| BDDCS | Biopharmaceutics Drug Disposition Classification System |
| CAM | Complementary alternative medicine |
| CRASD | Controlled release amorphous solid dispersion systems |
| CYPs | Cytochrome P450 |
| Cmax | Maximum (peak) drug concentration in the plasma, serum or whole blood |
| ER | Endoplasmic reticulum |
| F | the extent of drug bioavailability |
| GIT | Gastrointestinal tract |
| HMG-CoA | Hydroxyl-methyl-glutaryl coenzyme A |
| LNS | Lipid-based nanosystems |
| Microfold cells | M cells |
| NP(s) | Nanoparticle(s) |
| NLC | Nanostructured lipid carriers |
| NPs | nanoparticles |
| PK | pharmacokinetics |
| PLN | Polymer-lipid hybrid nanoparticles |
| PXR | Pregnane X receptor |
| SLN | Solid lipid nanoparticles |
| SJW | St. John wort |
| SNEDDS | Self-nanoemulsifying drug delivery systems |